Heart disease is the cause of morbidity and mortality in the industrialized world. While the use of human induced pluripotent stem cell (iPSCs) in regenerative medicine is a long-term goal. Recent technological advancement has enabled the generation of patient-specific and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. iPSC-CMs carry all the genetic information and therefore may be an ideal platform for elucidating disease modeling, drug screening, and cell therapy. Here I will discuss recent advances in this technology in the cardiovascular field.
Cardiac iPSCs for Drug Discovery
Video Apr 27, 2016
Key concepts discussed in this webinar will include: - Description of the in vitro test systems used to evaluate P-gp and - BCRP inhibition at Sekisui XenoTech and the advantages/disadvantages of these assays - Description of the test system qualification process that takes places prior to offering these assays in definitive studies - Comparison of IC50 values obtained from the different test systems - Comparison of IC50 and Ki values determined with the vesicle test system - How IC50 and Ki values are used to evaluate clinical relevanceWATCH NOW